Q/C Technologies, Inc. SEC filings QCLS
Q/C Technologies, Inc. has 604 filings in SEC EDGAR's recent list, going back to Mar 23, 2005. Its latest annual report, Form 10-K, was filed on Apr 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 18, 2026 (material agreement, officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Oct 20, 2025 | Oct 20, 2025 |
| PRE 14A | Preliminary proxy statement | Oct 10, 2025 | Oct 10, 2025 |
| DEF 14A | Proxy statement | Apr 21, 2025 | Dec 31, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 11, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | Nov 1, 2024 | Nov 1, 2024 |
| DEF 14A | Proxy statement | Jul 1, 2024 | Jul 1, 2024 |
| PRE 14A | Preliminary proxy statement | Jun 20, 2024 | Jun 20, 2024 |
| DEFA14A | Additional proxy material | Jul 21, 2023 | — |
| DEF 14A | Proxy statement | Jun 30, 2023 | Jun 30, 2023 |
| PRE 14A | Preliminary proxy statement | Jun 20, 2023 | Jun 20, 2023 |
| DEFA14A | Additional proxy material | Mar 22, 2023 | — |
| DEF 14A | Proxy statement | Mar 13, 2023 | Mar 13, 2023 |
| PRE 14A | Preliminary proxy statement | Mar 3, 2023 | Mar 3, 2023 |
| DEFA14A | Additional proxy material | Oct 26, 2022 | — |
| DEF 14A | Proxy statement | Oct 26, 2022 | Oct 26, 2022 |
| DEFA14A | Additional proxy material | Dec 13, 2021 | — |
| DEFA14A | Additional proxy material | Dec 3, 2021 | — |
| DEF 14A | Proxy statement | Nov 22, 2021 | Nov 22, 2021 |
| DEF 14A | Proxy statement | Jul 29, 2020 | Jul 29, 2020 |
| PRE 14A | Preliminary proxy statement | Jul 13, 2020 | Jul 13, 2020 |
| DEFA14A | Additional proxy material | Dec 5, 2019 | — |
| PRE 14A | Preliminary proxy statement | Nov 25, 2019 | Nov 25, 2019 |
| DEF 14A | Proxy statement | Nov 12, 2019 | Nov 12, 2019 |
| DEFA14A | Additional proxy material | Feb 5, 2019 | — |
| DEF 14A | Proxy statement | Feb 5, 2019 | Feb 5, 2019 |
| PRE 14A | Preliminary proxy statement | Jan 25, 2019 | Jan 25, 2019 |
| DEFA14A | Additional proxy material | Nov 26, 2018 | — |
| DEF 14A | Proxy statement | Nov 14, 2018 | Nov 14, 2018 |
| DEF 14A | Proxy statement | Jul 24, 2017 | Jul 24, 2017 |
| PRE 14A | Preliminary proxy statement | Jul 13, 2017 | Jul 13, 2017 |
| DEF 14A | Proxy statement | Nov 14, 2016 | Nov 14, 2016 |
| DEFA14A | Additional proxy material | Jun 26, 2015 | — |
| DEF 14A | Proxy statement | Jun 5, 2015 | Jun 5, 2015 |
| DEF 14A | Proxy statement | Oct 17, 2014 | Nov 4, 2014 |
Showing 34 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- QCLS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1321834
- Former names
- Q/C TECHNOLOGIES, INC. (until Oct 2, 2026); TNF Pharmaceuticals, Inc. (until Sep 10, 2025); MyMD Pharmaceuticals, Inc. (until Jul 1, 2024); Akers Biosciences, Inc. (until Apr 16, 2021); Akers Biosciences Inc (until Apr 11, 2017)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.